Pharmacological treatment of coronary artery disease with recombinant fibroblast growth factor-2: Double-blind, randomized, controlled clinical trial Academic Article Article uri icon

Overview

MeSH Major

  • Angioplasty, Balloon, Coronary
  • Coronary Artery Disease
  • Drug-Eluting Stents
  • Heart Transplantation

abstract

  • A single intracoronary infusion of rFGF2 does not improve exercise tolerance or myocardial perfusion but does show trends toward symptomatic improvement at 90 (but not 180) days.

publication date

  • February 19, 2002

Research

keywords

  • Academic Article

Identity

Digital Object Identifier (DOI)

  • 10.1161/hc0802.104407

PubMed ID

  • 11854116

Additional Document Info

start page

  • 788

end page

  • 93

volume

  • 105

number

  • 7